Trial Profile
Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ADHERE-S (NIS Brilique)
- Sponsors AstraZeneca
- 29 Jan 2020 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Sep 2018 Planned End Date changed from 30 Jun 2019 to 30 Sep 2019.